Eone Diagnomics Genome Center Co., Ltd. Stock Price

Eone Diagnomics Genome Center Co., Ltd. provides genetic information analysis services in South Korea. It engages in the genome research and development, genomic testing/screening, IT, and software activities. The company offers NICE, a non-invasive prenatal test, which detects a fetal DNA in maternal plasma for the pregnancy period; bebegene Plus, a newborn genetic screening test that analyzes base sequence and early screening genetic diseases; RiskCARE, which detects the risk of hereditary cancer early to prevent cancer; BRCARE, a genetic test in BRCA1 and BRCA2 genes for hereditary breast/ovarian cancer; genocube, a cancer and general disease prediction test; and Liquid Biopsy, a non-invasive alternative to tissue biopsy that helps to determine cancer treatments by identifying clinically relevant biomarkers. It also provides MYGENPLAN, which suggests personalized health care guide by analyzing personal genetic risks and current health status; TELOAGE that suggests personal genetic risk of diseases and personalized nutrition guide by analyzing current status of telomere; and gene2me Plus, which analyzes genes based on single nucleotide polymorphism array chip and predicts cancers and other diseases, as well as MyEyeGene, a genetic test for inherited eye diseases. Eone Diagnomics Genome Center Co., Ltd. was founded in 2013 and is based in Incheon, South Korea.